Post-care Instructions Apply gentle pressure if any bruising occurs at the injection site
R.BakhshiB
The PDS develops from large and relatively slow excitatory postsynaptic potentials mediated by AMPA and NMDA glutamate receptors activated by aberrant and large glutamate release within the foci
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Kasi PM, Rivero S, Aushev VN, Langer N, Wang CG, Cannon TL, Berim LD, Feinstein T, Grothey A, McCollom JW, Kalmadi SR, Zakari A, Dayyani F, Gravenor D, Meyer JM, Sharif S, Jurdi AA, Liu MC, Aleshin A, Kopetz S
Is the product Vegan?Yes, this is a vegan product